ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Cassava Sciences Inc

Cassava Sciences Inc (SAVA)

22.47
-1.28
(-5.39%)
At close: February 20 04:00PM
22.99
-0.76
( -3.20% )
After Hours: 07:29PM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

SAVA News

Press Releases Only

SAVA Discussion

View Posts
FooBarAndGrill FooBarAndGrill 2 weeks ago
Moderate AD will become a thing of the past.
👍️ 1
ranchhand71 ranchhand71 2 weeks ago
In a 6 page research report today Jones Resrach sets $75 target .
Partial comments include:
2-Year Data Continue to Show Robust Benefits, Primarily
in Mild Alzheimer's Patients
Summary: Cassava announced that mild Alzheimer’s disease patients
who received simufilam continuously for 24 months showed no decline in
cognition scores (ADAS-Cog11) in a two-year open-label safety study (n=47;
press release). As expected and seen in prior data update, the more progressed
moderate patients showed larger decline in cognition scores. Mild AD patients
represented approx. 60% of the enrolled patients in the open label trial, and our
prior conversations with the management indicated similar proportion of mild
AD patients in the two ongoing Phase 3 trials. To put it in context, the large
pharma trials for the approved AD drugs were in even earlier patients, i.e. early
stage AD patients or MCI, with even less disease progression. Management
has previously indicated to us that the Phase 3 trials are powered adequately
to show stat sig if data were to be stratified by mild and moderate AD patient
subgroups.
The open label study enrolled over 200 patients with mild-to-moderate
Alzheimer’s disease, AD (MMSE 16-26) that received 100 mg BID simufilam.
Taking into account that this study is open label and non-randomized for most
parts, we view this data as supportive for the ongoing Phase 3 trials. The safety
profile especially is a major advantage as potential long term treatment with
no drug-related serious adverse events after 24 months of treatment. With low
sales uptake of Leqembi in recent quarter (approx. $7.5mn), we see a clear
market for an effective oral drug with a clean safety profile.
We expect topline results from the Phase3 trials in the next 12-18 months—(1)
YE24: results from the 52-week RETHINK-ALZ trial, and (2) mid-2025: results
from the 76-week REFOCUS-ALZ trial. We note that Cassava previously
announced that 60-70% of study participants entered a Phase 3 study with
mild Alzheimer’s (MMSE 21-27) and the rest entered with moderate Alzheimer’s
(MMSE 16-20) . Both Phase 3 studies received a Special Protocol Assessment
(SPA) from the FDA and the Data and Safety Monitoring Board (DSMB)
recommended that both studies continue as planned, without modification.
Key points from the two-year open-label safety study:
¦ In 47 patients with mild AD who received simufilam continuously for two
years, the average ADAS-Cog showed a change of 0.07 points (± 1.51 SE)
from baseline to month 24. Mean ADAS-Cog scores at baseline was 15.2.
¦ In 40 patients with mild AD who received simufilam non-continuously, the
average ADAS-Cog score declined 1.04 point (± 1.65 SE) from baseline
to month 24. These patients received one year of simufilam, six months
on placebo and six months back on simufilam. Mean ADAS-Cog scores at
baseline was 14.6.
¦ In 32 patients with moderate AD who received simufilam continuously for
two years, the average ADAS-Cog score declined 11.05 points (± 1.91 SE)
Company and Market Data
Symbol SAVA
Price (Feb 6, 2024) $23.66
Market Cap (MM) $998
Enterprise Value $855 MM
Shares/Units Outstanding
(MM) 42.174
Free Float (MM) 38.2
Free Float % 90.6%
52-Week Range $12.32—$32.10
3-Month Avg. Daily Vol. 1,075,492
👍️ 2
FooBarAndGrill FooBarAndGrill 2 weeks ago
You're right. I believe the FDA will see the value for mild.
👍️ 1
runncoach runncoach 2 weeks ago
Setting aside it was an open label study with folks promoting the drug on social media in a way that is likely not beneficial, the real problem is the trial design has potentially set the final top line results up for failure. Today's results continued to enforce this thesis. The current trials include patients with MMSE between 16-26. The bottom half of those scores are the moderate ones who scored even worse than what was to be expected (-11) on today's data. We don't know how many will be in each group but it would seem unlikely that even if the mild patient group stabilizes as we saw today, it would overcome the moderate patients in a stat significant way. There is no doubt in my mind that the two groups scores will be broken out in a pre-specified but post hoc fashion that will satisfy many but could be piled on by naysayers and could take awhile for the FDA to sort things out, especially considering it will take the 2nd trial an additional 6 months to complete.

I am hopeful that the mild group is highly stat significant and that the FDA will allow SAVA to go down this path since there are nearly 2000 patients total in the 2 trials, making the mild group significant in numbers. Will be interesting to see how it plays out. JMHO
👍️ 1
FooBarAndGrill FooBarAndGrill 2 weeks ago
Ha, I think you're right.
👍️ 2 💯 1
WebSlinger WebSlinger 2 weeks ago
Doesn't almost everyone that gets AD start out as "mild"?
👍️ 1
FooBarAndGrill FooBarAndGrill 2 weeks ago
IMO, mild AD patients will now have a way out of this disease. So yeah.
👍️ 1
WebSlinger WebSlinger 2 weeks ago
That seems like great news, correct?
👍️ 2
runncoach runncoach 2 weeks ago
Saw this. It still makes me question the recruitment of the current trial. Hopeful that there are enough patients on the milder scale to get the job done.
👍️0
FooBarAndGrill FooBarAndGrill 2 weeks ago
In case you're wondering?
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
https://www.sec.gov/Archives/edgar/data/1069530/000117184324000648/exh_991.htm
👍️0
FooBarAndGrill FooBarAndGrill 2 weeks ago
I'm still holding. Volume went high (1-4M) for the first few days. Much less now..
👍️ 1
tknuncle tknuncle 2 weeks ago
Has anyone paid for the warrants or maybe sold some? I personally have converted the warrants to shares. I only had 48 which turned to 72 shares. I bought 30 shares the day it dropped but it was the day before the warrants cutoff date, so I didn't get any warrants for those shares. O well, my bag. Anyway, just wondering if anyone else has done this. Alot of people on Yahoo board are claiming they are still holding and waiting or turned their warrants into shares. Many are claiming to wait and see what the board members are doing with their warrants. GLTA
👍️0
ranchhand71 ranchhand71 3 weeks ago
Risky;over priced and infusions are time consuming ,create lots of plastic waste going into landfills. SAVA has a much better alternative
👍️0
FooBarAndGrill FooBarAndGrill 3 weeks ago
Biogen is pulling the plug on its Aduhelm (Aducanumab) Alzheimer’s disease drug.
https://www.google.com/search?q=Aduhelm
👍️0
ranchhand71 ranchhand71 4 weeks ago
Thank you.i have seen that but hard to know if true and why aren’t there a lot more???
👍️0
runncoach runncoach 4 weeks ago
Yeah I don't like to see stuff like this at all but I sure pray the the drug is beneficial!
👍️0
FooBarAndGrill FooBarAndGrill 4 weeks ago
This is a YT compilation of some anecdotal testimonials.

I'm a skeptic regarding this type of data but here it is.
👍️0
FooBarAndGrill FooBarAndGrill 1 month ago
Bonus Warrant Status Page:
https://www.cassavasciences.com/static-files/5b796146-4e6a-41e6-9909-5e084bcacfec
👍️ 1 💜 1
FooBarAndGrill FooBarAndGrill 1 month ago
SHORTS have to purchase 5,554,850 warrants on the open market.

As of Jan 1, 2024 $SAVA short count was 13,887,126 shares*
OWNERS of 10 $SAVA shares have rights to 4 warrants. **
(13,887,126 x 0.4) = 5,554,850

It's hard out here for the SHORTS.

* https://www.nasdaq.com/market-activity/stocks/sava/short-interest
** https://www.sec.gov/Archives/edgar/data/1069530/000149315224000298/form424b2.htm
👍️ 2
FooBarAndGrill FooBarAndGrill 1 month ago
SAVAW on reg sho list. Can you say SQUEEEEEEZE?
https://www.nasdaqtrader.com/trader.aspx?id=RegSHOThreshold
👍️ 2
soupa1 soupa1 1 month ago
Next week will be $10+. GL
👍️0
runncoach runncoach 1 month ago
Nice
👍️0
FooBarAndGrill FooBarAndGrill 1 month ago
Warrants did well today.
SAVAW $7.30 +3.30 (82.5%)
👍️ 1
FooBarAndGrill FooBarAndGrill 1 month ago
I'm guessing the outcome measures of this clinical trial will provide data needed to supplement the NDA. I don't see this going anywhere beyond that.

Primary Outcome Measures :
AUC of total radioactivity, parent drug and metabolite(s) in plasma.
Cmax of total reactivity, parent drug and metabolite(s) in plasma.
Tmax of total reactivity, parent drug and metabolite(s) in plasma.
Half-life of total reactivity, parent drug and metabolite(s) in plasma.
Elimination rate constant of total reactivity, parent drug and metabolite(s) in plasma.

Secondary Outcome Measures :
Percentage of total radioactivity recovered versus time.
Plasma and whole blood concentration of total radioactivity versus time.
Plasma concentration of parent drug and metabolite(s) versus time.
👍️0
FooBarAndGrill FooBarAndGrill 1 month ago
Cassava has developed a radio-isotope version of simufilam: [14C]-Simufilam. The organic molecule is created using Carbon-14 in place of C-12. The resulting molecule may be used as a research aid.
A P1 clinical trial has been logged at clinicaltrials.gov.
👍️ 1
sab63090 sab63090 2 months ago
Apparently a judge wants lawsuit dismissed....as reported by Adam F....good luck
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
Warrants are quoted here:
https://ih.advfn.com/stock-market/NASDAQ/cassava-sciences-SAVAW/stock-price
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
$SAVA Warrants are now listed in my account.
👍️ 1
FooBarAndGrill FooBarAndGrill 2 months ago
The warrant dividend will be based on the number of shares you hold at OPEN of business on 12/21/2023. Thus 12/20/2023 (tomorrow) is really the last day to play.
👍️0
ranchhand71 ranchhand71 2 months ago
These new Driectors were no doubt briefed on inforation that is not yet public.....
👍️0
redspinelpinktopaz redspinelpinktopaz 2 months ago
thumbs up, gotcha. Still think ALVR will change medicine, even though it's moved somewhat.
👍️0
runncoach runncoach 2 months ago
Absolutely
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
It's a little complicated for shorts as well. LOL.
👍️0
runncoach runncoach 2 months ago
Yeah a little complicated but we'll see how much money that brings in. Could be enough to avoid raising before results...at least on any less than favorable terms. Very creative. No idea where the share price lands once it all plays out, but certainly a positive.
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
That's different!
It looks like I have 3 choices.
(1) Exercise the warrant to buy a share at a guaranteed $33.
(2) Trade the warrant under the SAVAW ticker.
(3) Wait for the 20-day bonus period TBA
👍️0
runncoach runncoach 2 months ago
Got to love this warrant deal on multiple levels! Nice job management! Sure blew a hole in the "dead money" thesis when insiders were "propping up" the stock.
👍️0
runncoach runncoach 2 months ago
Strong follow through today again. This thing has made a lot of traders big money. Approximately 12 months to results. Can't get here soon enough
👍️0
ranchhand71 ranchhand71 2 months ago
Thank you for the perspective. Appreciated
I think it is quite significant that the new Directors have such strong relevant backgrounds and have been brought on the Board to help manage the next phase which may well include a signifcant investment from a global partner and the rollout of the drug globally in the 36 months ahead,
👍️ 1
FooBarAndGrill FooBarAndGrill 2 months ago
Almost any clinical will yield some super-responders. Even existing treatments like Aricept have great results with a few people. It just doesn't mean much to the big picture.
That said, I occasionally see some 2nd-hand stories on different platforms such as Twitter and Reddit.
👍️0
ranchhand71 ranchhand71 2 months ago
With more than 1000 families having a loved one in trials why are we not hearing anecdotal evidence or comments about progress?
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
Another update on clinicaltrials.gov yesterday.
The Phase III OLE trial (NCT05575076) is enrolling by invitation. The number of sites participating in this OLE increased from 57 to 83. This is good.
👍️ 1
runncoach runncoach 2 months ago
Thx
👍️ 1
FooBarAndGrill FooBarAndGrill 2 months ago
Appointed Three New Members Board of Directors
Claude Nicaise, MD ... Pierre Gravier, MS ... Robert Anderson, Jr
https://www.cassavasciences.com/news-releases/news-release-details/cassava-sciences-appoints-three-new-members-its-board-directors
👍️ 1
FooBarAndGrill FooBarAndGrill 2 months ago
Yeah, so ... The same could be said for other companies we hold.
Anyway, I enjoy the up days and this is one of them. Positive news.
👍️ 1
runncoach runncoach 2 months ago
Any news of why it's up almost 20% today?
👍️0
georgejjl georgejjl 2 months ago
Unfortunately Remi Barbier is still the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors.
👍️0
runncoach runncoach 3 months ago
I'm always hopeful in all these alternative plays as the SOC plaque attack drugs aren't worth the money
👍️ 2
grich1 grich1 3 months ago
Thanks, they are really hopeful since
Buntanetap is the only drug to attack multiple neurotoxic proteins.

Best wishes to you.
👍️ 1
runncoach runncoach 3 months ago
I had researched them in the past. In theory I liked their story about synaptic health and how the drug potentially worked. Preclinical it had a secondary impact on PKCe and Hgf and as you know, this is something I have researched. When I looked at details of how they were running their clinical trials I had concerns about the memantine free period before dosing so have never bought in. I still think they have a shot but maybe longer than I first thought. Of course at current prices it may be a better gamble than in the past.

I still follow the sector but I'm just not seeing a revolutionary treatment at this time. Doesn't mean none of these will have limited success, or potential approvals in some groups, or nice sales, or even make shareholders good money. I've been hoping for a true game changer and I don't currently see one. JMHO
👍️ 1
grich1 grich1 3 months ago
Have you looked at Annovis bio?
👍️0

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com